stockrow
Friday 6 November 2026
Export XNCR’s income statement to Excel — free account
Xencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
36.11
2.06
+6.05%
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Total debt
Xencor, Inc.'s total debt at the end of fiscal 2025 was $119.7M, down 26.8% from $163.6M in fiscal 2024. Over the past ten years it has ranged from $10.7M (fiscal 2019) to $189.5M (fiscal 2023); the current reading is higher than 71% of that period. Xencor, Inc. ranks 77th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $119.7M | (26.81%) |
| FY2024 | $163.6M | (13.66%) |
| FY2023 | $189.5M | 217.74% |
| FY2022 | $59.6M | 75.55% |
| FY2021 | $34.0M | 192.13% |
| FY2020 | $11.6M | 8.33% |
| FY2019 | $10.7M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Dec 2025 | $119.7M | (22.43%) |
| Mar 2025 | $154.4M | (5.64%) |
| Dec 2024 | $163.6M | (5.32%) |
| Sep 2024 | $172.8M | (3.87%) |
| 22 more quarters | Free account |
Against its own ten years
Low $10.7M
High $189.5M
Ten-year median
$59.6M
Current reading's percentile
71
Total debt against peers
| Company | Total debt |
|---|---|
| ZLAB Zai Lab Limited Unsponsored ADR compare | $252.4M |
| ADMA ADMA Biologics Inc compare | $198.9M |
| XNCR Xencor, Inc. | $119.7M |
| RCUS Arcus Biosciences, Inc. compare | $102.0M |
| BEAM Beam Therapeutics Inc. compare | $100.4M |
| PHVS Pharvaris N.V. compare | $559.6K |
| NAMS NewAmsterdam Pharma Company N.V. compare | $94.9K |
| RXRX Recursion Pharmaceuticals, Inc. compare | $93.0K |
| MBX MBX Biosciences, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement